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Original article
Defining a positive circumferential resection margin in
oesophageal cancer and its implications for adjuvant treatment
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Background: A positive circumferential resection margin (CRM) has been associated with a poorer
prognosis in oesophageal and oesophagogastric junctional (OGJ) cancer. The College of American
Pathologists defines the CRM as positive if tumour cells are present at the margin, whereas the Royal
College of Pathologists also include tumour cells within 1 mm of this margin. The relevance of these
differences is not clear and no study has investigated the impact of adjuvant therapy. The aim was to
identify the optimal definition of an involved CRM in patients undergoing resection for oesophageal
or OGJ cancer, and to determine whether adjuvant radiotherapy improved survival in patients with an
involved CRM.
Methods: This was a single-centre retrospective study of patients who had undergone attempted
curative resection for a pathological T3 oesophageal or OGJ cancer. Clinicopathological variables and
distance from the tumour to the CRM, measured to ± 0.1 mm, were correlated with survival.
Results: A total of 226 patients were included. Sex (P= 0·018), tumour differentiation (P= 0·019),
lymph node status (P < 0·001), number of positive nodes (P< 0·001), and CRM distance (P= 0·042) were
independently predictive of prognosis. No significant survival difference was observed between positive
CRM 0-mm and 0·1–0·9-mm groups after controlling for other prognostic variables. Both groups had
poorer survival than matched patients with a CRM at least 1 mm clear of tumour cells. Among patients
with a positive CRM of less than 1 mm, those undergoing observation alone had a median survival
of 18·6 months, whereas survival was a median of 10 months longer in patients undergoing adjuvant
radiotherapy, but otherwise matched for prognostic variables (P= 0·009).
Conclusion: A positive CRM of 1 mm or less should be regarded as involved. Adjuvant radiotherapy
confers a significant survival benefit in selected patients with an involved CRM.
Presented in part to a meeting of the Digestive Disorders Federation, Liverpool, UK, June 2012; published in
abstract form as Gut 2012; 61(Suppl 2): A260
Paper accepted 7 March 2013
Published online 24 April 2013 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.9145
Introduction
Oesophageal cancer is the sixth leading cause of cancer
death worldwide and surgical resection remains the
cornerstone of attempted curative therapy1. Microscopic
identiﬁcation of residual tumour at the proximal or
distal resection margin (termed R1) increases the risk
of recurrence and disease-related mortality2. Patients
are therefore most likely to beneﬁt from surgery if a
microscopically complete (R0) resection is achieved.
The importance of microscopic disease at the circumfer-
ential resection margin (CRM) was ﬁrst reported in 1993; a
higher risk of local recurrence was observed when tumour
deposits were present at the radial margin of oesophageal
resection specimens3. Parallels have been drawn between
rectal and oesophageal cancer as both can extend radially
into surrounding tissues. In rectal cancer, identiﬁcation of
tumour cells at or within 1mm of the CRM increases the
risk of local recurrence and disease-related mortality4–6.
The Royal College of Pathologists (RCP) has deﬁned an
involved CRM for oesophageal cancer as the presence of
tumour cells within 1mm of the radial resection margin, in
keeping with the rectal cancer classiﬁcation7. In contrast,
 2013 British Journal of Surgery Society Ltd British Journal of Surgery 2013; 100: 1055–1063
Published by John Wiley & Sons Ltd
1056 J. R. O’Neill, N. A. Stephens, V. Save, H. M. Kamel, H. A. Phillips, P. J. Driscoll and S. Paterson-Brown
the College of American Pathologists (CAP) considers
the CRM as involved if tumour cells are observed at the
margin8. Several studies have found a poorer prognosis for
patients with an involved CRM, although the deﬁnition
used has varied9–16. In some of these studies, however,
tumour differentiation9,16 and number of involved lymph
nodes9,10,12 were not considered in multivariable analyses,
potentially limiting the conclusions drawn. Two papers
reported a prognostic impact when patients were stratiﬁed
by distance from the tumour to the CRM15,16. One
study reported no survival difference between groups
with a positive CRM of 0mm versus 0·1–0·9mm15.
The other, involving patients undergoing neoadjuvant
chemoradiotherapy followed by surgery, identiﬁed a
poorer prognosis only for patients with a CRM of 0mm16.
A positive CRM must reﬂect the extent of wall invasion
(tumour category, T) and there is a clear link between
increasing T category and the likelihood of lymph node
involvement. The central importance of lymph node
metastases in determining the prognosis of patients with
oesophageal or oesophagogastric junctional (OGJ) cancer
is widely accepted17,18. To reﬂect this, the seventh edition
of the tumour nodemetastasis (TNM) staging system strat-
iﬁes node status, with node-positive disease classiﬁed as N1
for one or two, N2 denoting three to six and N3 denoting
seven or more positive nodes19. The effect of distance
of the tumour to the CRM on survival can therefore be
assessed only when confounding prognostic variables such
as lymph node metastasis have been taken into account.
A uniﬁed deﬁnition of the involved CRM would allow
straightforward comparison between trials. In turn this
might lead to some clarity regarding the use of adjuvant
therapies, in the absence of good evidence at present. The
aims of this study were therefore: to establish whether
an involved CRM was associated with poorer prognosis
and to determine which classiﬁcation provided the most
useful prognostic information in patients undergoing
neoadjuvant chemotherapy followed by surgery, or surgery
alone for oesophageal or OGJ cancer; and to examine the
inﬂuence of adjuvant radiotherapy on survival in selected
patients with an involved CRM.
Methods
De-identiﬁed treatment and outcome data for patients
undergoing attempted curative resection of oesophageal or
OGJ cancer between 1994 and 2010 at the Royal Inﬁrmary
of Edinburgh were obtained from a prospectively main-
tained surgical audit database. Only clinical data obtained
as part of routine treatment were used for this study. No
additional patient consent was needed and ethical approval
was not required.
Patients with a pathological (p)T3, as deﬁned in the
seventh edition of the TNM staging manual19, adenocar-
cinoma or squamous cell carcinoma of the mid or distal
oesophagus or oesophagogastric junction (Siewert type
I–III) were included. Patients with macroscopic residual
disease at surgery (R2 resection), tumour within 1mm of
the proximal or distal resection margins, or unavailability
of original pathology specimens for review, and those
who died within 30 days of surgery were excluded. Demo-
graphic, surgical and oncological treatment, pathological
and survival data were available for all remaining patients.
Survival was deﬁned as time from diagnosis to death from
any cause or last follow-up with primary or tertiary care,
censoring in January 2012.
All patients were staged using a combination of
computed tomography (CT), CT–positron emission
tomography and endoscopic ultrasonography, and selected
for surgical treatment by a multidisciplinary team
comprising surgeons, gastroenterologists, oncologists,
radiologists and pathologists. All resections consisted of
en bloc oesophageal dissection with mediastinal and upper
abdominal lymphadenectomy, with the approach tailored
to the tumour location and patient physiology. From 2001
onwards, neoadjuvant chemotherapy was offered routinely
to patients without contraindicating co-morbidity and
with clinical T3 disease and/or nodal metastasis identiﬁed
on preoperative staging. This consisted of either two cycles
of cisplatin and 5-ﬂuorouracil, or three or four cycles
of epirubicin, cisplatin and capecitabine. Neoadjuvant
radiotherapy was not used.
The oesophageal CRM was inked by the reporting
pathologist before dissection. Fixed specimens were then
sliced into 5-mm transverse segments, and representative
blocks incorporating the closest proximity of the tumour
to the inked margin were embedded for histological
review. The shortest distance from the tumour to the
CRM was recorded to ± 0·1mm. As UK standards of
pathology reporting changed during the study period, all
specimens were re-reported for this analysis by a single
expert pathologist using the criteria in the seventh edition
of the TNM staging manual19. Tumour differentiation
was described by the most poorly differentiated area in the
resection specimen.
The pathological ﬁndings for each resection were
discussed at a multidisciplinary meeting. Selected patients
with a positive CRM closer than 1mm were offered
adjuvant radiotherapy comprising 50Gy delivered in 20
daily fractions over 4weeks using a three- or four-ﬁeld
technique. The target radiotherapy volume was planned
using a combination of preoperative CT, endoscopic
ultrasonography, operative and pathological ﬁndings. The
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ﬁeld was designed to encompass the preoperative site of
the tumour with a minimum radial, superior and inferior
margin of 2 cm. Radiotherapy was generally commenced 8
weeks after surgery, postoperative recovery permitting.
Statistical analysis
Continuous variables are summarized as median (range)
or mean (95 per cent conﬁdence interval) as appropriate.
Categorical variables were compared using the χ2 test.
To determine the effect of demographic and pathologi-
cal variables on survival, univariable analysis was performed
using the Kaplan–Meier method with a log rank test of
signiﬁcance for categorical co-variables and Cox regression
for continuous co-variables20,21. Co-variables found to be
signiﬁcantly associated with survival on univariable analysis
(P< 0·050) were assessed in a Cox proportional hazards
model22. Owing to the bias in established prognostic
variables across groups stratiﬁed by CRM distance, the
method of propensity score matching analysis (PSMA) was
applied23. This method has the advantage over Cox regres-
sion of generating two groups matched for confounders
and differing by the treatment of interest so the magnitude
of treatment effect can be estimated. This technique has
been reviewed thoroughly elsewhere24 but, brieﬂy, PSMA
uses binary logistic regression to incorporate and balance
all known confounders by their ability to predict the
presence or absence of the investigated variable. With
known co-variables the probability of the presence of the
investigated variable can be derived, termed the propensity
score. Propensity scores are calculated for all patients and
then each case in the treated group is paired with a control
in the untreated group with a similar propensity score. A
nearest neighbour with replacement strategy was used as
this allows the closest approximation of scores to generate
the best matched groups that differ only by the treatment
investigated25. As the propensity score-matched groups
were selected rather than independent, Cox regression
stratiﬁed by quintiles of propensity score was used to
evaluate the signiﬁcance of survival differences26,27. To
estimate the magnitude of survival differences between
propensity score-matched groups, the Wilcoxon matched-
pairs signed rank test was used, with pairs deﬁned as
informative if the shorter survivor was not censored27.
Statistical signiﬁcance was deﬁned as P< 0·050. All
statistical analysis was performed using SPSS software
version 19.0.0 (IBM, Armonk, New York, USA).
Results
A total of 428 patients underwent resection during the study
period. Some 202 patients were excluded for the following
reasons: non-pT3 tumours (149), tumour less than 1mm
from the proximal or distal resection margin (26),
postoperative death within 30 days (12), blocks unavailable
for pathological review (10), histology other than
adenocarcinoma or squamous cell carcinoma (3) and R2
resection (2). A summary of demographic and pathological
characteristics of the remaining 226 patients is provided
in Table 1. The median age was 64 (39–82) years. The
estimated 5-year survival rate of this cohort was 25 per cent,
with a median survival of 28 (4–181) months and a median
follow-up of 35 months for the 70 surviving patients.
Tumours were resected via a right thoracotomy and
laparotomy (Ivor Lewis oesophagectomy) in 190 patients
(84·1 per cent), left thoracolaparotomy in 25 (11·1
per cent), transhiatal resection in ﬁve (2·2 per cent),
extended total gastrectomy in ﬁve (2·2 per cent), and
thoracoscopy and laparotomy in one patient (0·4 per cent).
The median nodal harvest was 21 (3–56) nodes, with more
than ten nodes examined in 92·9 per cent of patients.
Sex, tumour differentiation, lymph node status, number
of positive lymph nodes and shortest distance from tumour
cells to the CRM were all signiﬁcantly associated with
survival (Table 1). Patient age, tumour site, histology, oper-
ation type, year of resection and neoadjuvant chemotherapy
use had no association with survival on univariable analysis.
In the multivariable model, number of involved nodes
(P< 0·001), node status (P< 0·001), tumour differentiation
(P = 0·019), sex (P = 0·018) and CRM distance (P = 0·042)
remained independently predictive of survival.
Survival stratified by circumferential resection
margin
When patients were grouped by distance from the closest
point on the tumour to the CRM (0mm, 0·1–0·9mm,
1mm or more), there was a signiﬁcant association with
prognosis (P = 0·019 across groups) (Table 1, Fig. 1a).
Patients with a close or directly involved CRM had more
extensive lymphatic metastasis (P = 0·002) (Table 2). To
correct for this, propensity score-matched groups were
created that were closelymatched for those variables shown
above to affect prognosis (Table 2). Propensity score-
stratiﬁed univariable Cox regression analysis revealed a
signiﬁcantly poorer survival when the distance to the
CRMwas 0mm compared with 1mm or more (P = 0·033);
the hazard ratio (HR) for death was 1·70 (95 per cent
conﬁdence interval 1·04 to 2·78). There was no difference
between groups with a positive CRM of 0mm versus
0·1–0·9mm (P = 0·549). A signiﬁcantly poorer survival
was also noted for the CRM 0·1–0·9-mm group when
compared independently with a propensity score-matched
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Table 1 Cohort characteristics and survival analysis
No. of patients (n= 226)* Median survival (months)† Univariable P¶ Multivariable P**
Sex 0·001 0·018
M 183 (81·0) 23·0 (18·5, 27·5)
F 43 (19·0) 69·0 (23·3, 114·7)
Tumour location 0·664 –
Mid oesophagus 24 (10·6) 28·0 (11·7, 44·3)
Distal oesophagus 61 (27·0) 29·0 (18·0, 40·0)
Type I junctional 77 (34·1) 22·0 (16·1, 27·9)
Type II junctional 48 (21·2) 27·0 (15·1, 38·9)
Type III junctional 16 (7·1) 50·0 (0, 136·2)
Neoadjuvant therapy 0·189 –
Yes 130 (57·5) 29·0 (20·6, 37·4)
No 96 (42·5) 25·0 (18·8, 31·2)
Histology 0·051 –
ACC 184 (81·4) 25·0 (19·3, 30·7)
SCC 42 (18·6) 44·0 (29·6, 58·4)
Differentiation 0·002 0·019
Well 5 (2·2) 76·0 (0, 160·3)
Moderate 92 (40·7) 34·0 (25·8, 42·2)
Poor 129 (57·1) 21·0 (17·0, 24·9)
Node status < 0·001 < 0·001
N0 44 (19·5) 84·0 (36·3, 131·7)
N1 65 (28·8) 31·0 (26·7, 35·3)
N2 65 (28·8) 28·0 (19·3, 36·7)
N3 52 (23·0) 14·0 (12·0, 16·0)
CRM (mm) 0·019 0·042
0 47 (20·8) 18·0 (13·0, 23·0)
0·1–0·9 83 (36·7) 28·0 (18·7, 37·4)
≥ 1 96 (42·5) 33·0 (25·8, 40·2)
Continuous variables‡
Age (years) 64 (39–82) 1·00 (0·98, 1·02)§ 0·681# –
No. of positive lymph nodes 3 (0–23) 1·12 (1·09, 1·16)§ < 0·001# < 0·001
Values in parentheses are *percentages and †95 per cent conﬁdence intervals unless indicated otherwise; ‡values for continuous variables are median
(range) with §hazard ratios. ACC, adenocarcinoma; SCC, squamous cell carcinoma; CRM, circumferential resection margin. ¶Log rank test, except #Cox
regression; **Cox proportional hazards model.
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Fig. 1 Kaplan–Meier curves for a all patients and b propensity score-matched patients stratiﬁed by distance to the circumferential
resection margin (CRM)
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Table 2 Characteristics of circumferential resection margin groups
Unselected patients† Propensity score-matched to CRM 0mm‡
Propensity score-matched
to CRM 0.1–0·9mm§
CRM 0mm
(n=47)
CRM 0·1–0·9mm
(n= 83)
CRM≥ 1mm
(n=96)
CRM 0mm
(n=47)
CRM 0·1–0·9mm
(n= 47)
CRM≥ 1mm
(n=47)
CRM 0·1–0·9mm
(n=83)
CRM ≥ 1mm
(n=83)
Sex
M 40 66 77 40 40 40 66 66
F 7 17 19 7 7 7 17 17
Neoadjuvant
therapy
Yes 23 51 56 23 20 25 51 61
No 24 32 40 24 27 22 32 22
Histology
ACC 41 63 80 41 43 42 63 60
SCC 6 20 16 6 4 5 20 23
Differentiation
Well 2 3 0 2 2 0 3 0
Moderate 14 36 42 14 13 16 36 28
Poor 31 44 54 31 32 31 44 55
Node status
N0 4 18 22 4 6 3 18 24
N1 11 20 34 11 9 11 20 18
N2 11 29 25 11 10 7 29 25
N3 21 16 15 21 22 26 16 16
Median survival
(months)*
18·0 (13·0,
23·0)
28·0 (18·7,
37·4)
33·0 (25·8,
40·2)
18·0 (13·0,
23·0)
21·4 (11·9,
30·8)
28·0 (18·0,
38·0)
28·0 (18·7,
37·4)
47·2 (43·3,
51·1)
*Values in parentheses are 95 per cent conﬁdence intervals. CRM, circumferential resection margin; ACC, adenocarcinoma; SCC, squamous cell
carcinoma. Comparison of node status: †P = 0·002, ‡P = 0·825, §P = 0·739 (χ2 test).
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Fig. 2 Scatter plots of survival differences between propensity score-matched pairs. Survival differences from informative pairs are
shown: a circumferential resection margin (CRM) 0 mm versus 0·1–0·9 mm (n= 43), b CRM 0 mm versus 1 mm or more (n= 41) and
c CRM 0·1–0·9 mm versus 1 mm or more (n= 64). Dashed red lines represent median values. a P = 0·837, b P = 0·038, c P = 0·005
(Wilcoxon matched-pairs signed rank test)
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Table 3 Comparison of unselected and propensity score-matched
patients with a positive circumferential resection margin of less
than 1mm treated by adjuvant radiotherapy or observation alone
Unselected† Propensity score-matched‡
Observation
(n=52)
Adjuvant
radiotherapy
(n= 23)
Observation
(n= 23)
Adjuvant
radiotherapy
(n=23)
Sex
M 44 17 16 17
F 8 6 7 6
Neoadjuvant
therapy
Yes 52 23 23 23
No 0 0 0 0
Histology
ACC 48 13 14 13
SCC 4 10 9 10
Differentiation
Well 2 1 1 1
Moderate 14 10 10 10
Poor 36 12 12 12
Node status
N0 5 11 14 11
N1 8 9 7 9
N2 18 3 2 3
N3 21 0 0 0
CRM (mm)
0 17 7 5 7
0·1–0·9 35 16 18 16
Adjuvant
radiotherapy
Yes 0 23 0 23
No 52 0 23 0
Median survival
(months)*
17·0 (10·7,
23·3)
96·0 (14·9,
177·0)
18·6 (8·6,
28·6)
96·0 (14·9,
177·0)
*Values in parentheses are 95 per cent conﬁdence intervals. ACC,
adenocarcinoma; SCC, squamous cell carcinoma; CRM, circumferential
resection margin. Comparison of node status: †P< 0·001, ‡P = 0·667
(χ2 test).
group with a CRM of 1mm or more (P = 0·029); the HR
was 1·53 (1·04 to 2·27) (Table 2).
There was no difference in length of survival between
propensity score-matched pairs selected from positive
CRM 0-mm and CRM 0·1–0·9-mm groups when adverse
prognostic factors such as lymph node metastasis were
taken into account. Compared with propensity score-
matched patients with a positive CRM of 1mm or greater,
survival was signiﬁcantly poorer by a median of 5months
for patients with a CRM of 0mm and by 7months for
those with a CRM of 0·1–0·9mm (Fig. 2).
Treatment of the positive circumferential
resection margin
The cohort contained 75 patients who had undergone
neoadjuvant chemotherapy and had a positive CRM closer
than 1mm. Within this group, 23 patients underwent
adjuvant radiotherapy. There was a signiﬁcant selection
bias for these patients, with a predominance of squamous
cell carcinomas, and patients with N0 and N1 disease
(P< 0·001) (Table 3). The remainder of the group
underwent postoperative observation only and had a
signiﬁcantly poorer survival (P = 0·001) (Fig. 3a).
Propensity score matching was applied to create two
well matched groups differing only in the use of adjuvant
radiotherapy. Patients receiving adjuvant radiotherapy had
a median survival of 96·0 (95 per cent conﬁdence interval
14·9 to 177·0) months compared with 18·6 (8·6 to 28·6)
months for thosemanaged by observation alone (P = 0·009)
(Table 3, Fig. 3b); the HR for death was 0·50 (0·30 to 0·84).
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Fig. 3 Kaplan–Meier survival curves for a unselected patients and
b propensity score-matched patients with a circumferential
resection margin smaller than 1 mm treated by adjuvant
radiotherapy or observation
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Fig. 4 Scatter plot of survival differences between propensity
score-matched patients with a circumferential resection margin
smaller than 1 mm treated by adjuvant radiotherapy or
observation only. Data from informative pairs are presented
(n= 16). Dashed red line represents the median difference.
P = 0·021 (Wilcoxon matched-pairs signed rank test)
Among propensity score-matched pairs, the estimated
survival beneﬁt for adjuvant radiotherapy was calculated
as a median of 10 (range −43 to 112) months (Fig. 4).
Discussion
This study of pT3 oesophageal and OGJ cancers showed
that a positive CRM of 1mm or less was the optimal
cut-off to identify patients with a poorer survival, and
therefore supports the RCP classiﬁcation. This is in
agreement with seven previous studies that demonstrated a
CRM of less than 1mm to be independently predictive of
prognosis9–13,15,28. In contrast, two studies have reported
only a directly involved CRM to be independently
predictive of prognosis14,16. One of these studies involved
132 patients with pT3 oesophageal adenocarcinoma
undergoing surgery alone, and compared RCP and CAP
classiﬁcations16. Only a positive CRM of 0mm and histo-
logical vascular invasion were independently predictive of
survival, although only 43 patients had a positive CRM of
1mm or more so the study may have been underpowered
to detect a survival difference between groups. The study
was also unusual in failing to demonstrate an association
between node status and survival. The second study
examined 135 pT3 oesophageal cancers, but again only 52
patients had a positive CRM of 1mm or greater and lack
of power may have limited the conclusions drawn14.
In the present study, the rate of CRM involvement
and lymph node harvest were comparable with those
in other series of resected pT3 cancers. Like others, a
signiﬁcant imbalance in known prognostic variables was
found between groups stratiﬁed by the shortest distance
from the tumour to the CRM15,29. Previous studies
have attempted to control for the discrepancies in node
status or tumour differentiation by considering only node-
positive or -negative patients, or subdividing tumours by
differentiation10–12. Although this approach can correct for
one or two confounders, it is at the expense of diminishing
discriminatory power. Multivariable analysis can correct
for confounders, and Cox regression incorporating known
prognostic variables established CRM group as indepen-
dently predictive of prognosis in the present analysis.
PSMA permitted assessment of the contribution of the
CRM to survival by correcting for known prognostic
variables. This revealed equivalent survival in patients
with a positive CRM of 0mm and those with a CRM
of 0·1–0·9mm when the effect of known confounders
was eliminated. Both groups had a signiﬁcantly poorer
survival than matched patients with a positive of CRM
1mm or more, indicating that the RCP rather than the
CAP deﬁnition of an involved CRM is more appropriate.
PSMA has been used in one other study to assess
the effect of the CRM on survival after resection of
oesophageal cancer30. Although the authors found no
survival difference between matched groups, all of the
patients underwent chemoradiotherapy followed by
surgery and the patient numbers were small (44 for CRM
less than 1mm versus 1mm or more; 8 for CRM 0mm
versus CRM more than 0mm).
Differences in preoperative treatment limit comparisons
between studies. Neoadjuvant chemoradiotherapy has
been associated with a lower R1 rate than neoadjuvant
chemotherapy31,32. A systematic review of trials of
neoadjuvant chemoradiotherapy followed by surgery
supports these ﬁndings, with a 15 per cent average rate
of positive CRM less than 1mm33. In the present study,
among patients with a positive margin after neoadjuvant
chemotherapy and surgery, there was a signiﬁcant survival
beneﬁt of 10months and a twofold relative reduction in the
risk of death for those treated with adjuvant radiotherapy
compared with observation alone. This beneﬁt was
apparent after correction for selection bias by propensity
score matching for known prognostic variables. The idea
that there may be a survival beneﬁt with radiotherapy
in the context of microscopic residual disease seems
appealing.
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The study does have limitations. In common with
all observational studies, there was bias through patient
selection. The management of patients with oesophageal
cancer also changed during the study period, with the
introduction of neoadjuvant chemotherapy leading to
tumour downstaging in some patients. In an effort to
minimize this effect, only patients with clinical T3
tumours before treatment were included. The present
study also reported overall rather than disease-speciﬁc
survival. This seems appropriate, as the majority of deaths
after oesophagectomy for cancer are the result of this
disease. Furthermore, the actual cause of death is often
unclear without post-mortem examination, and death is
often attributed to oesophagogastric cancer regardless
of other possible conditions34. It is possible that the
observed survival beneﬁt following adjuvant radiotherapy
resulted from selection bias in favour of patients who
were physiologically more robust and able to withstand a
month of radiotherapy shortly after major surgery. This
bias was not corrected for by thematching analysis. For this
reason, although the results are encouraging, they merit
independent conﬁrmation.
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